Affiliation:
1. Clinical Center Niš, Clinic for Hematology and Clinical Immunology, Niš
2. Clinical Center Niš, Clinic for Hematology and Clinical Immunology, Niš + Faculty of Medicine, Niš
3. Clinical Center of Serbia, Belgrade
4. Clinical Center of Serbia, Belgrade + Faculty of Medicine, Belgrade
Abstract
Background/Aim. Follicular lymphoma (FL) is a B-cell tumor usually with
indolent clinical course, yet in some cases the course of the disease can be
very aggressive. The aim of the re-search was to determine distribution of
patients into prognostic groups based on the International Prognostic Index
(IPI) and Folicular Lymphoma International Prognostic Index (FLIPI) criteria,
as well as to determine the importance of classifying patients into the
prognostic groups, since this could potentially have the influence on
selection of the treatment modality. Methods. The retrospective study was
performed on 257 patients with follicular lymphoma diagnosed between January
2000 and April 2011. Results. Based on the IPI score, 153 (59.53%) patients
had low risk, 57 (22.18%) low intermediate risk, 15 (5.84%) high intermediate
risk, 9 (3.50%) high risk, whereas the classification of 23 patients
diagnosed with FL remained with unknown risk according to the IPI. Based on
the FLIPI prognostic index, 113 (43.97%) patients had low risk, 70 (27.24%)
intermediate risk and 51 (19.84%) high risk, whereas the classification of 23
(8.95%) patients remained unknown. On the basis of the FLIPI 2 prognostic
index, 48 (18.68%) patients had low risk, 145 (56.42%) intermediate risk and
41 (15.95%) high risk. The classification into prognostic groups for 23
(8.95%) patients remained unknown. According to the IPI, FLIPI and FLIPI 2
there were the patients that required treatment in all the risk groups.
Conclusion. The FLIPI and FLIPI 2 effectively identify patients at high risk,
thus helping in treatment decision for each single patient.
Publisher
National Library of Serbia
Subject
Pharmacology (medical),General Medicine